Plain-English translation of NCT06634030 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial tested whether a wound matrix saturated with recombinant human platelet-derived growth factor B () could help heal large surgical wounds on the head and neck better than a standard saline-based matrix. After participants had skin cancer removed and were left with wounds too large to close with stitches, researchers randomly assigned them to receive either the growth factor-enhanced treatment or the standard treatment. The study tracked how well the wounds healed, how much scarring occurred, and how participants felt during recovery.
Some skin cancer removal surgeries leave large wounds that cannot be closed with stitches alone and do not need a skin graft. Researchers wanted to see if adding a growth factor to the healing matrix could speed up healing and reduce scarring compared to standard care.
After consenting and screening, participants received either the growth factor-enhanced or standard matrix placed into their wound during a baseline procedure. They returned for a follow-up visit on day 6 for suture removal and wound care, then again at weeks 4 and 8 for clinical exams and photographs. Starting on day 7 through day 56, participants took daily photos of their wound at home using a mobile app while changing their dressing, and reported pain and any problems weekly through phone calls, emails, or in-person visits.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States